Degrader-Antibody Conjugates (DACs): Tumor-Specific Delivery of Potent Degraders
Advancing a New Therapeutic Class
DACs represent a next generation of antibody-drug conjugates (ADCs) by combining the catalytic activity of a Targeted Protein Degrader (TPD) with the specificity of an antibody. This new therapeutic modality has the potential for enhanced efficacy and improved safety in two ways. First, replacing the highly toxic ADC payload with degraders may improve both safety and efficacy. Second, DACs are more selective than traditional degraders because DACs deliver degraders specifically to tumor cells. Thus, by combining degrader technology with ADCs, DACs have the potential to be a next generation alternative to both traditional degraders and current ADCs.